Loading stock data…
ODTX
$17.09-0.03 (-0.18%)
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases.
Historical Price
Price (Candle)
Synthesizing Whystock Narrative...
Quarterly Financials
| Metric (USD) | Q4 2024 | Q3 2024 |
|---|---|---|
| Total Revenue | $1.75M | — |
| Gross Profit | — | — |
| Operating Income | -$37.12M | — |
| Net Income | -$35.93M | — |
Peer Comparison
JNJUNHPFE
Fundamentals
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, whic...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$806.21M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
9.39%
Volume
Today's trading volume
268,844